About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Vir Biotechnology image

Vir Biotechnology

Rank#5163
Market Cap1.80B
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Historyarrow

Vir Biotechnology was founded in 2016 by President and CEO Dr. George Scangos and Chief Scientific Officer Peter Thompson. Together they bring decades of experience in biotechnology drug discovery, development and commercialization. Expressing their deep conviction in the power of monoclonal antibodies to cure disease, George and Peter have driven Vir since day one. Over the past four years, Vir has assembled world-class scientific and commercial leadership, raised over $530M in venture capital, established strategic collaborations and partnerships, built state-of-the-art facilities and developed a promising pipeline of product candidates for large unmet medical needs.

Missionarrow
At Vir, we believe that immunology holds the greatest promise to revolutionize the treatment of complex and serious infectious diseases. We strive to make an impactful difference in the lives of patients by bringing together the most innovative science with the highest standards for safety, effectiveness, and availability.
Visionarrow
To become the leading research-driven, discovery- fueled, pioneering organization in the development of immunology-based treatments and breakthrough medicines.
Referencesarrow

https://in.investing.com/equities/vir-biotechnology-inc

https://finance.yahoo.com/quote/VIR/profile?p=VIR

https://www.crunchbase.com/organization/vir-biotechnology

https://sec.report/CIK/0001706431

https://companiesmarketcap.com/

https://www.vir.bio

Share

Leadership team
D
Dr. George A. Scangos Ph.D. (Pres, CEO & Director)
M
Mr. Howard Horn (Exec. VP, CFO & Sec.)
D
Dr. Ann M. Hanly Ph.D. (Exec. VP & Chief Technology Officer)
Products / Services
Biopharma, Biotechnology, Health Care, Medical
Number of Employees
100 - 500
Address
San Francisco, California, United States
Established
2016-01-01
Company Registration
SEC CIK number: 0001706431
Net Income
$1B – $20B
Revenue
$1B+
Traded as
VIR
Website
https://www.vir.bio
Social Media
linkedinx
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo